Avaliação da acuidade visual e da pressão intraocular no tratamento do edema macular diabético com triancinolona intravítrea

Rezende, Marcussi Palata; Dias, Alana Ferreira Gomes; Oshima, Akiyoshi; Andrade, Eric Pinheiro de; Serracarbassa, Pedro Durães

doi:10.1590/s0004-27492010000200006

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, cataract, ocular hypertension, and glaucoma are frequently encountered with triamcinolone therapy 26–29. We did not observe cataract or glaucoma in our study.…”

Section: Discussioncontrasting

confidence: 68%

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results

Demir¹,

Oba²,

Gülkılık³

et al. 2011

OPTH

View full text Add to dashboard Cite

Purpose:To present the functional and anatomic changes after intravitreal bevacizumab in eyes with macular edema (ME) due to branch retinal vein occlusion (BRVO).Design:The study was a retrospective study.Materials and methods:The study included 31 patients with ME due to BRVO. We compared the examination findings of patients with ME before and after intravitreal bevacizumab therapy at 12 months. The study included patients who had macular edema secondary to BRVO treated with bevacizumab. The therapy was started in the first week after occlusion. The initial therapy was three intravitreal bevacizumab injections at monthly intervals with 1.25/0.05 mL bevacizumab. Patients with a baseline visual acuity less than 0.5 (logarithm of the minimum angle of resolution [logMAR] 0.30), central macular thickness (CMT) more than 290 μm, and no neovascularization were included. Patients with diabetes mellitus or a history of intravitreal triamcinolone or grid laser photocoagulation therapy or ischemic BRVO were excluded. The retreatment criteria were as follows: increased CMT more than 100 μm combined with a loss of visual acuity of five or more letters. The statistical analysis of this study was carried out by paired samples t-test (SPSS). A P value of less than 0.05 was considered to be statistically significant.Results:This retrospective study included 33 eyes of 31 patients (20 women, 11 men; mean age was 55.30 ± 9.62 years (range 36–75 years). Patients received a mean of 5.3 injections during 12 months of follow-up. The best corrected visual acuity increased from 0.66 ± 0.20 (logMAR) at baseline to 0.22 ± 0.13 (logMAR) (t = 15.42; P < 0.001) at month 12. The CMT decreased from 494.15 ± 104.16 μm at baseline to 261.79 ± 45.36 μm at month 12 (− 232.36 ± 109.98 μm); P < 0.001). No bevacizumab-related systemic or ocular adverse effects following intravitreal drug injections were observed. The majority of patients required reinjection(s) treatment for ME (84.9%).Conclusion:Intravitreal therapy using bevacizumab appears to be an effective primary treatment option for ME due to BRVO. No serious ophthalmologic or systemic side effects were observed for intravitreal bevacizumab therapy. The main disadvantage of bevacizumab therapy is the requirement of multiple injections in order to maintain visual and anatomic improvements.

show abstract

“…However, cataract, ocular hypertension, and glaucoma are frequently encountered with triamcinolone therapy 26–29. We did not observe cataract or glaucoma in our study.…”

Section: Discussioncontrasting

confidence: 68%

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results

Demir¹,

Oba²,

Gülkılık³

et al. 2011

OPTH

View full text Add to dashboard Cite

show abstract

“…Rezende et al 24 Microaneurismas, espessamento da membrana basal, oclusão focal dos capilares e quebra na barreira retiniana aumentam a permeabilidade vascular.…”

Section: Autor Principais Achadosunclassified

Diabetes melito: hiperglicemia crônica e suas complicações

Ferreira

Saviolli

Valenti

et al. 2011

Arq. Bras. Ciên. Saúde

View full text Add to dashboard Cite

ResumoIntrodução: O termo diabetes melito descreve uma desordem metabólica de múltipla etiologia, caracterizado por hiperglicemia crônica decorrente de defeitos na secreção e/ou ação da insulina. O diabetes melito é classificado em tipo 1 e 2, diabetes gestacional e outros tipos. A hiperglicemia crônica é o fator primário desencadeador das complicações do diabetes melito. Objetivo: Descrever os mecanismos fisiopatológicos das complicações crônicas e dos distúrbios metabólicos decorrentes da hiperglicemia. Métodos: Foram consultadas as bases de dados do SciELO, Lilacs e Medline. As consultas incluíram artigos registrados entre 1999 e 2010, nas línguas portuguesa e inglesa. Resultados: A hiperglicemia promove a formação dos produtos de glicação avançada (AGEs), responsáveis por complicações macrovasculares. A insulinopenia estimula a secreção de hormônios contrainsulínicos como glucagon, cortisol, catecolaminas e hormônio do crescimento. Iniciam-se processos catabólicos (lipólise e proteólise). Ácidos graxos são captados pelas células hepáticas. Ocorre síntese de acetil-Coa que é convertida em corpos cetônicos. A retenção de corpos cetônicos no plasma provoca acidose metabólica. Alterações na fisiologia ocular são derivadas da opacificação do cristalino e de modificações vasculares retinianas. Nefropatia diabética é a complicação crônica microvascular que compromete a função renal por aumento da membrana basal glomerular. A neuropatia diabética envolve a ativação da via do poliol, a síntese de AGEs e a redução do fluxo sanguíneo neural. Conclusão: A patogênese das alterações fisiológicas e metabólicas decorrentes da hiperglicemia compreende mecanismos fisiológicos, biológicos e bioquímicos que afetam a qualidade de vida do organismo.Palavras-chave: diabetes mellitus; hiperglicemia; complicações do diabetes; cetoacidose diabética. AbstractIntroduction: The term diabetes mellitus describes a metabolic disorder of multiple etiology, which is characterized by chronic hyperglycemia resulting from

show abstract

Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion

et al. 2014

View full text Add to dashboard Cite

show abstract

Avaliação da acuidade visual e da pressão intraocular no tratamento do edema macular diabético com triancinolona intravítrea

Cited by 4 publications

References 25 publications

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results

Diabetes melito: hiperglicemia crônica e suas complicações

Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion

Contact Info

Product

Resources

About